45 signals · bluesky, h1b_lca, newsapi +2 more
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Moderate risk indicators present across data sources.
Auto-generated from public signals — AI summary pending. Based on 4 recent signals.
Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal TradingView
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech Pharmaceutical Executive
Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech Pharmaceutical Executive
Biotech subsidiary of Roche focused on cancer.
Based on 45 signals across 5 sources · snapshot 7 Oct 2026
Strong: enough recent evidence to trust this score.
Overall community sentiment for Genentech is mixed based on public signals as of 7 Oct 2026.
Based on 45 signals across 5 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
$ALEC — Alector's licensing deal with Genentech and Parkinson's program drove recent coverage, alongside mixed technical indicators and negative profitability. Upside discussed: Licensing agreement with Genentech valued at $1.27 billion. https://market-scanner.net/tickers/ALEC.US #ai #trading
$ALEC — Alector's licensing deal with Genentech and Parkinson's program drove recent coverage, alongside mixed technical indicators and negative profitability.